Vaccines Archives

News and Trends 3 Nov 2016

CEVEC is Revolutionizing Industrial Protein & Viral Vector Production

CEVEC just filed a Biologics Master File (BB-MF) to the FDA for its CAP technology, which outperforms all current standards in the production of gene therapy vectors and glycosylated human proteins. CEVEC is a Biotech with the mission of raising the industrial standard for the large-scale production of glycosylated proteins, viral vaccines and gene therapy […]

November 3, 2016 - 2 minutesmins - By External Contributor

News and Trends 18 Oct 2016

€4M Grant for a Cancer Vaccine that could Bench its Competitors

Hookipa just secured a huge grant from the Austrian government. The plan is to develop the strongest HPV vaccine ever and claim its place in the €2B head and neck cancer market. Hookipa, one of the hottest Biotechs in Vienna, develops vaccines based on a new class of viral vectors. Its platform has impressed the public sector and secured €4.16M from the Austrian […]

October 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Oct 2016

This Biotech makes DNA Vaccines and Gene Therapy Possible in Lapland

After Grenoble, we fly north to Finland to meet Santa’s reindeer and earn his good graces before Christmas. After a trip to the sauna and down time with Angry Birds, whose creator hails from the country, we moseyed over to visit FIT Biotech, our biotech of the week. City: Tampere, Finland Founded: 1995 Employees: 12 + […]

October 14, 2016 - 2 minutesmins - By Evelyn Warner

Screenshot 2016 10 12 at 12.23.30 PM e1476267908354

News and Trends 12 Oct 2016

Transgene teams up with big Players against HPV Head and Neck Cancer

Transgene is partnering with Merck and Pfizer to develop a combined therapy for head and neck cancer squamous cell carcinoma (HNSCC) caused by human papiloma virus (HPV) infections. A successful outcome will let the team access a €2B market niche. Transgene has been struggling for a while: last year it had to fire 40% of its workforce […]

October 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 09 29 at 4.53.52 PM e1475160985987

News and Trends 30 Sep 2016

Tailored Cancer Vaccines? NousCom is working on it!

We aren’t leaving Switzerland yet! We took a scenic train to Basel in order to meet nousCom, a very young biotech developing cancer vaccines. City: Basel, Switzerland Founded: 2015 Employees: unknown Financial Data: €12M raised in series A Mission: NousCom is a Biotech that develops next generation cancer vaccines with patient- and tumor-specific antigens. Their vaccines combine viruses […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Boehringer buys a €210M ticket to Virus-based Immuno-Oncology

Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […]

September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Sep 2016

German Biotech allies with Genentech in battle for Cancer Vaccine

BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […]

September 21, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 6 Sep 2016

“This Phase I could Pioneer Needle-free Vaccines”, DBV’s CEO

How annoying are needle vaccinations? Very … But the French billion-euro Biotech DBV Technologies wants to bring a paradigm shift via its Anti-allergy Patch platform! I got to chat with the founder & CEO, Pierre-Henri Benhamou, for more insights. DBV’s success continues to amaze me. It’s not only close to solving the global peanut and […]

September 6, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 22 Aug 2016

This new vaccine could tackle both Zika and Dengue at once

These potentially fatal diseases have reached pandemic proportions and are starting to threaten the Western world. Excivion (UK) and Xenetic (US) have announced a partnership to develop a combined vaccine for Dengue and Zika Viruses using new vaccine delivery technology. Following on Sanofi’s initiatives to combat the spread of Zika and Dengue viruses, a transatlantic partnership between […]

August 22, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 1 Aug 2016

Biotech producer of Vaccines goes public on Nasdaq Stockholm

After raising €2M in its successful IPO, ExpreS2ion Biotech starts trading on Nasdaq First North in Stockholm – a real milestone for this industrial spin-out. Expres2ion Biotech started out in 2010, as a spin-out of a Danish company focused on human antibodies, Affitech. Affitech itself has had a convoluted path. It was initially Norwegian, then merging with […]

August 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

liver hepatitis c gilead vaccine HCV metavax

News and Trends 27 Jul 2016

New Vaccine could solve the problem of the costly Gilead’s Hepatitis C ‘Cure’

Artes Biotechnology and Burnet Institute will join their proprietary technologies to develop a novel vaccine for the Hepatitis C virus. This could create a more affordable solution to reduce the high HCV-related mortality. Hepatitis C remains a health problem around the world. WHO estimates that more than half a million people die every year from […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

cell medimmune influenza a antibody biotech

News and Trends 21 Jul 2016

‘Winner Antibody’ holds promise as universal Influenza A Vaccine

MedImmune and Humabs have reasons to be happy. Their candidate for an Influenza A vaccine has made it into well-known journal, Cell, boasting a unique affinity to the virus with multiple mechanisms to stop infection. The promising candidate is MEDI8852, an antibody initially developed by Humabs (Switzerland). It targets Influenza A virus (the group of viruses known as avian flu), […]

July 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us